# Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Source: https://onco.cc/trials/nct03643133/  
OnCo record `nct03643133` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mifamurtide in Osteosarcoma, run by UNICANCER, active and no longer recruiting.

## Summary

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients is a phase 2 interventional study registered as NCT03643133 by UNICANCER, with 60 participants planned, started 2018-10-23 and due to reach its primary completion in 2026-09. Interventions recorded: Mifamurtide, EI or M-API regimen depending on patient age. Conditions recorded: Osteosarcoma.

Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03643133
- Phase: 2
- Setting: Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)
- Sponsor: UNICANCER
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT03643133: https://clinicaltrials.gov/study/NCT03643133

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Mifamurtide](https://onco.cc/drugs/mifamurtide/)

---
JSON: https://onco.cc/api/v1/entities/nct03643133.json